The deal will add Milan-based Temas’ range of regulatory consulting, pharmacovigilance and training offering to Quintiles Commercial Italia’s range of contract research services.
A Quintiles spokeswoman told Outsourcing-pharma.com that: “Health reforms in many different markets across Europe [require that] biopharma must demonstrate the value of its drugs to a wider range of stakeholders in order to get a product to market effectively.
She explained that although most pharma companies know how to gain regulatory approval for a new drug in different countries, they often lack the skills needed to assess the needs stakeholders in local markets.
“This acquisition in Italy underlines Quintiles commitment to the allying with biopharma to navigate the complexities of market access.”
According to Italian news agency MF Dow Jones News Temas will continue to operate as an independent brand, albeit integrated with elements that refer to membership of Quintiles.
Temas CEO Nadia Peviani, who will play a consultancy during the transition, told the newswire that: "Being acquired by a large group such as Quintiles is the culmination of a long collaboration between two companies that have always shared the results, values and ethical principles.”
The Temas deal is one of a number of approaches Quintiles uses to increase its market access capabilities.
In May last year the CRO took over a UK regulatory and market access team formerly operated by Nycomed, which continued to provide the Swiss firm with services on a contractual basis.